SAVANNAH
SAVANNAH: Phase II Trial of Savolitinib + Osimertinib for Advanced EGFRm NSCLC With MET Amplification or Overexpression After Progressing on Osimertinib

Released: April 02, 2025

Expiration: October 01, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: April 02, 2025

Expiration: October 01, 2025